Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wyeth Moves To Broaden Prevnar: Prepares Offer For Crucell

This article was originally published in The Pink Sheet Daily

Executive Summary

Crucell would fit Wyeth’s ongoing effort to extend geographic base for vaccines and provide new candidates and technologies to provide depth to the company’s vaccine R&D effort.

You may also be interested in...



Emilio Emini Is The Key To Wyeth Vaccines

In touting the $68 billion proposed deal for Wyeth, Pfizer CEO Jeff Kindler repeatedly cited Wyeth's vaccine business as a key part of the deal. But what exactly will Pfizer get after scooping up this unit? Two crucial assets - one is a product and the other is a person

Who Stays, Who Goes? Tricky Guessing On Wyeth/Pfizer’s Keeper Deals

"Buyer beware" is more often "seller beware" in the case of takeovers such as Pfizer's proposed mega-grab of Wyeth

Emilio Emini Is The Key To Wyeth Vaccines

In touting the $68 billion proposed deal for Wyeth, Pfizer CEO Jeff Kindler repeatedly cited Wyeth's vaccine business as a key part of the deal. But what exactly will Pfizer get after scooping up this unit? Two crucial assets - one is a product and the other is a person

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068572

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel